
GNFT Stock Forecast & Price Target
GNFT Analyst Ratings
Bulls say
Genfit SA has demonstrated a positive outlook, driven by the reported €59 million in sales from its partner Ipsen for the drug Iqirvo in primary biliary cholangitis (PBC), indicating strong market potential and anticipated acceleration in growth. Additionally, Ipsen's presentation of favorable Phase 2 data in progressive familial intrahepatic cholestasis (PSC) suggests the potential for unlocking further milestones, which could enhance revenue prospects. Furthermore, Genfit's diversified pipeline, coupled with strategic partnerships and a proven execution history, reduces the inherent risks associated with biopharmaceutical development and supports a favorable long-term investment perspective.
Bears say
Genfit SA faces significant clinical and regulatory uncertainties regarding its pipeline assets, which poses a risk to the company's future growth and stability. The recent decision to halt development of VS-01 due to serious adverse events highlights potential safety concerns that may hinder the progression of their treatments in critical patient populations. Furthermore, the company's reliance on external financing to support pipeline expansion introduces additional risks, particularly if current capital is insufficient to meet future development needs.
This aggregate rating is based on analysts' research of Genfit - ADR and is not a guaranteed prediction by Public.com or investment advice.
GNFT Analyst Forecast & Price Prediction
Start investing in GNFT
Order type
Buy in
Order amount
Est. shares
0 shares